PLX-200 is an oral compound comprised of gemfibrozil, an FDA-approved lipid regulating agent. According to the company, gemfibrozil’s ability to cross the blood-brain barrier and its established ...

The average one-year price target for Protalix BioTherapeutics (NYSEAM:PLX) has been revised to $11.22 / share. This is a decrease of 12.00% from the prior estimate of $12.75 dated January 11, 2026.

As we look forward to 2026, we remain focused on building with our partners a growing, profitable business and an innovative pipeline for patients with high-need rare diseases. A core element of this ...

Pluxee (ENXTPA:PLX) has been sliding this year, with the share price down nearly 29% year to date, even as revenue and net income continue to edge higher. That disconnect is catching value investors ...

Darcy Bourne named winner of Social Impact Award at the UK Sport PLx Awards for her work across her charity Raising Her Game and Beyond our Game. The annual event was hosted in Leeds, where nine award ...

Parallax Worlds, a startup building hyper-realistic virtual simulations to stress-test robots before deployment, today announced it raised $4 million in a seed round. Developing and deploying robots ...

Protalix BioTherapeutics, Inc. misses on earnings expectations. Reported EPS is $0.02914 EPS, expectations were $0.06. Operator: Greetings, and welcome to the Protalix BioTherapeutics, Inc. Third ...

Greetings, and welcome to the Protalix BioTherapeutics Third Quarter Financial and Business Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now ...

I’ve spent the past few years trying to understand something that often feels beyond understanding—how artificial intelligence, particularly large language models, actually thinks. Or at least, how ...

Fabry disease is a rare genetic lysosomal storage disorder in which the body lacks sufficient amounts of an enzyme that breaks down fats. The companies requested to approve the dosing regimen of 2 ...

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) is among the hidden penny stocks to buy now. During the first quarter, Goldman Sachs Group Inc. expanded its holdings in Protalix BioTherapeutics, Inc ...

Plexium has raised $60.1 million, providing an infusion of cash for the recently slimmed-down protein degrader specialist three years on from its breakout year. The biotech put itself on the map in ...